Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2007 | Letter to the Editor

¹¹C/¹⁸F-choline PET or¹¹C/¹⁸F-acetate PET in prostate cancer: may a choice be recommended?

Authors: Cristina Nanni, Paolo Castellucci, Mohsen Farsad, Domenico Rubello, Stefano Fanti

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2007

Excerpt

Dear Sir, …

Sarma AV, Schottenfeld D. Prostate cancer incidence, mortality, and survival trends in the United States: 1981–2001. Semin Urol Oncol 2002;20(1):3–9.PubMedCrossRef

Beerlage HP, de Reijke TM, de la Rosette JJ. Considerations regarding prostate biopsies. Eur Urol 1998;34(4):303–12.PubMedCrossRef

Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 2000;163(4):1144–8, discussion 1148–9.PubMedCrossRef

Sedelaar JP, Vijverberg PL, De Reijke TM, de la Rosette JJ, Kil PJ, Braeckman JG, et al. Transrectal ultrasound in the diagnosis of prostate cancer: state of the art and perspectives. Eur Urol 2001;40(3):275–84.PubMedCrossRef

Briganti A, Chun FK, Salonia A, Zanni G, Scattoni V, Valiquette L, et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 2006;49(6):1019–26, discussion 1026–7.PubMedCrossRef

Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39(6):990–5.PubMed

Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Rien J, et al. In vivo uptake of [¹¹C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005;32:668–73.PubMedCrossRef

Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, et al. Value of [¹¹C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [¹⁸F]fluorodeoxyglucose-positron emission tomography. J Urol 2003;169(4):1337–40.PubMedCrossRef

de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ.¹¹C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003;44(1):32–8, discussion 38–9.PubMedCrossRef

10.

de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Visualization of prostate cancer with¹¹C-choline positron emission tomography. Eur Urol 2002;42(1):18–23.PubMedCrossRef

11.

de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by¹¹C-choline PET. J Nucl Med 2003;44(3):331–5.PubMed

12.

Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of¹¹C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46(10):1642–9.PubMed

13.

Reske SN, Blumstein NM, Neumaier B, Gottfried HW, Finsterbusch F, Kocot D, et al. Imaging prostate cancer with¹¹C-choline PET/CT. J Nucl Med 2006;47(8):1249–54.PubMed

14.

Hara T, Kondo T, Hara T, Kosaka N. Use of¹⁸F-choline and¹¹C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg 2003;99(3):474–9.PubMedCrossRef

15.

Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al. [¹⁸F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006;33(12):1387–98.PubMedCrossRef

16.

Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, et al.¹¹C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43(2):181–6.PubMed

17.

Yoshimoto M, Waki A, Yonekura Y. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001;28:117–22.PubMedCrossRef

18.

Kotzerke J, Volkmer BG, Glatting G, van den Hoff J, Gschwend JE, Messer P, et al. Intraindividual comparison of [¹¹C]acetate and [¹¹C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003;42(1):25–30.PubMed

Title: 11C/18F-choline PET or 11C/18F-acetate PET in prostate cancer: may a choice be recommended?
Authors: Cristina Nanni
Paolo Castellucci
Mohsen Farsad
Domenico Rubello
Stefano Fanti
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2007
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0491-5

At a glance: The STEP trials

Springer Medicine

¹¹C/¹⁸F-choline PET or¹¹C/¹⁸F-acetate PET in prostate cancer: may a choice be recommended?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2007

Lymphoscintigraphic and intraoperative detection of sentinel lymph nodes

Are there adaptive changes in the human brain of patients with Parkinson’s disease treated with long-term deep brain stimulation of the subthalamic nucleus? A 4-year follow-up study with regional cerebral blood flow SPECT

Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study

Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma

Radio-guided surgery with the use of [99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract

Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence